Journal
THERANOSTICS
Volume 12, Issue 7, Pages 3719-3746Publisher
IVYSPRING INT PUBL
DOI: 10.7150/thno.72594
Keywords
Antibody-based therapy; Immunotherapy; Drug delivery system; Controlled release
Categories
Funding
- Open Research Fund of Chengdu University of Traditional Chinese Medicine State Key Laboratory Southwestern Chinese Medicine Resources, Health and Family Planning Commission of Chengdu-Key disciplines of clinical pharmacy, Chengdu University New Faculty Sta [2081921097]
Ask authors/readers for more resources
Antibody-based cancer therapy has emerged as an efficient therapeutic strategy with diverse clinical manifestations and applications. Various drug delivery platforms have been developed to enhance therapeutic efficacy. Antibody-based drug delivery systems play an important role in cancer therapy by addressing the current challenges of antibody application and utilizing advanced drug delivery technologies.
In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, various drug delivery platforms have been developed to improve the bioavailability, delivery convenience, and reduced toxicity towards increased therapeutic efficacy of antibodies. Herein, we emphasize the clinical manifestations of various antibody-based tumor therapies, highlighting their mechanisms and applications for cancer therapy. Further, based on the problems to be solved in the current clinical application of antibodies, and combined with the advanced drug delivery technologies, we discuss the roles of antibody-based drug delivery systems (DDSs) in cancer therapy, such as enhanced patient compliance and regulating the tumor microenvironment for combined therapy. By expounding the importance of DDSs and discussing the challenges and prospects of their implementation, we suggest that pharmaceutical enterprises and scientists develop appropriate antibody-based delivery platforms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available